CD4 and neoplasm: In the LLC subcutaneous tumor model, the proportions of CD8+ TILs in the control group, the PDT group, the BMS202 group and the combined treatment group were 0.960±0.221%, 8.523±1.963%, 3.044±0.701% and 9.146±2.106%, respectively, and the proportions of CD4+ infiltrating lymphocytes in four groups were 2.063±0.631%, 4.631±1.216%, 2.589±0.75%, and 6.100±1.554%, respectively.